Jalil Khan, MD
Internal Medicine · Lewisville, TXNPI 1821183435
Payments from drug & device makers
Across 181 payments — averaging $258.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$28K
- Pfizer$16K
- AbbVie$1K
- Boehringer Ingelheim$415
- Novo Nordisk$324
- GSK$251
- plus $1K from 23 others
Across 1 payment — averaging $1290.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Food & beverage$2,681100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $27,610 |
| Pfizer | 15 | $16,134 |
| AbbVie(2 entities) | 8 | $1,034 |
| Boehringer Ingelheim | 27 | $415 |
| Novo Nordisk | 19 | $324 |
| GSK | 17 | $251 |
| Amgen | 10 | $172 |
| Astellas Pharma US Inc | 8 | $132 |
| Lilly USA, LLC | 5 | $81 |
| Abbott | 3 | $63 |
| Paratek Pharmaceuticals, Inc. | 4 | $61 |
| Exact Sciences | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $51 |
| Genentech USA, Inc. | 2 | $41 |
| Medtronic | 2 | $39 |
| Eisai Inc. | 2 | $34 |
| Novartis | 2 | $34 |
| Smith+Nephew | 2 | $32 |
| Melinta Therapeutics, LLC | 2 | $28 |
| Merck | 2 | $26 |
| Johnson & Johnson | 2 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $20 |
| KCI USA, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Si-bone, Inc. | 1 | $17 |
| Radius Health, Inc. | 1 | $16 |
| Reprise Biomedical, Inc. | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $11 |
How this compares
$46,776 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $127,275 |
| JardianceEmpagliflozin | 59 | $75,219 |
| EliquisApixaban | 58 | $67,667 |
| FarxigaDapagliflozin Propanediol | 34 | $42,486 |
| XifaxanRifaximin | 11 | $41,689 |
| JanuviaSitagliptin Phosphate | 36 | $38,757 |
| MounjaroTirzepatide | 14 | $28,734 |
| MyrbetriqMirabegron | 25 | $24,125 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $22,707 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 18 | $19,164 |
| XareltoRivaroxaban | 12 | $18,206 |
| LinzessLinaclotide | 16 | $17,127 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $10,199 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $10,001 |
| Diclofenac Sodium | 86 | $5,088 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $324 | $127,27575 claims |
| Boehringer IngelheimJardiance | $415 | $75,21959 claims |
| PfizerEliquis | $16,134 | $67,66758 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $27,610 | $52,68549 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $51 | $41,68911 claims |
| MerckJanuvia | $26 | $38,75736 claims |
| Lilly USA, LLCMounjaro | $81 | $28,73414 claims |
| Astellas Pharma US IncMyrbetriq | $132 | $24,12525 claims |
| Johnson & JohnsonXarelto | $24 | $18,20612 claims |
| AbbVieLinzess | $1,034 | $17,12716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Lewisville
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.